Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.

@article{Pohl2005IndependentAA,
  title={Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.},
  author={Marc A. Pohl and Samuel Blumenthal and Daniel J. Cordonnier and Fernando de {\'A}lvaro and Giacomo Deferrari and Gilbert M. Eisner and Enric Esmatjes and Richard E Gilbert and Lawrence G. Hunsicker and Jos{\'e} B Lopes de Faria and Ruggero Mangili and Jack L Moore and Efrain Reisin and Eberhard Ritz and Guntram Schernthaner and Samuel Spitalewitz and Hilary Tindall and Roger A. Rodby and E Jonathan Lewis},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2005},
  volume={16 10},
  pages={3027-37}
}
Elevated arterial pressure is a major risk factor for progression to ESRD in diabetic nephropathy. However, the component of arterial pressure and level of BP control for optimal renal outcomes are disputed. Data from 1590 hypertensive patients with type 2 diabetes in the Irbesartan Diabetic Nephropathy Trial (IDNT), a randomized, double-blind, placebo-controlled trial performed in 209 clinics worldwide, were examined, and the effects of baseline and mean follow-up systolic BP (SBP) and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 109 extracted citations

Similar Papers

Loading similar papers…